Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > ADC > CD27 Ligand > CDL-H5255

Human CD27 Ligand / CD70 Protein, Llama IgG2b Fc Tag, low endotoxin

  • Synonym
    CD70,CD27LG,TNFSF7,TNFSF7G,CD27L
  • Source
    Human CD27 Ligand, Llama IgG2b Fc Tag (CDL-H5255) is expressed from human 293 cells (HEK293). It contains AA Ser 52 - Pro 193 (Accession # NP_001243.1).
    Predicted N-terminus: Glu
  • Molecular Characterization
    Online(Ser 52 - Pro 193) NP_001243.1

    This protein carries a llama IgG2b Fc tag at the N-terminus.

    The protein has a calculated MW of 75.5 kDa. The protein migrates as 140-160 kDa under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin
    Less than 0.01 EU per μg by the LAL method.
  • Purity

    >95% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, 25 mM Arginine, 150 mM NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
Human CD27 Ligand, Llama IgG2b Fc Tag (Cat. No. CDL-H5255) SDS-PAGE gel

Human CD27 Ligand, Llama IgG2b Fc Tag on SDS-PAGE under non-reducing (NR) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

Bioactivity-ELISA
Human CD27 Ligand, Llama IgG2b Fc TagHuman CD27 Ligand, Llama IgG2b Fc Tag (Cat. No. CDL-H5255) ELISA bioactivity

Immobilized Human CD27 Ligand, Llama IgG2b Fc Tag (Cat. No. CDL-H5255) at 2 μg/mL (100 μL/well) can bind Human CD27, His Tag (Cat. No. CD7-H522b) with a linear range of 2-39 ng/mL (QC tested).

Human CD27 Ligand, Llama IgG2b Fc TagHuman CD27 Ligand, Llama IgG2b Fc Tag (Cat. No. CDL-H5255) ELISA bioactivity

Immobilized Human CD27 Ligand, Llama IgG2b Fc Tag (Cat. No. CDL-H5255) at 2 μg/mL (100 μL/well) can bind Biotinylated Human CD27, Fc,Avitag (Cat. No. TN7-H82F6) with a linear range of 0.3-20 ng/mL (Routinely tested).

Please note that there may be a cross-reaction between anti-human IgG Fc antibodies and llama IgG Fc tag, also between anti-llama IgG Fc antibodies and human IgG Fc tag.
  • Background
    Cluster of Differentiation 70 (CD70) is also known as CD27 ligand (CD27L / CD27LG), TNFSF7, TNFSF7G, is a type II transmembrane glycoprotein belonging to the TNF superfamily (TNFSF) and is a surface antigen found on activated T-and B-lymphocytes and mature dendritic cells. Binding of CD70 to its receptor CD27 induces in priming, effector functions, differentiation and memory formation of T-cells, and thus is invloved in the biological processes including T-cell activation, the proliferation of costimulated T-cells, as well as the generation of cytolytic T-cells. CD70 on T cells provides costimulatory signals that are required for T cell proliferation, clonal expansion and the promotion of effector T cell formation. CD70 on mouse B cell has been shown to inhibit terminal differentiation of activated B cells into plasma cells and enhances commitment to memory B cell responses. CD70 induces proliferation and IFNγ production, on NK cells.
  • Clinical and Translational Updates
      
  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

Comments (0)


ETD of in-stock products: 2 business days

Price(USD) : $380.00

Price(USD) : $2500.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:3 Details
  • Latest Research Phase:Phase 2 Clinical

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

Contact Us

+1  800-810-0816 (US)
+86 400-682-2521 (AP)

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message